Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807)
about
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.Subinhibitory concentrations of cefpodoxime alter membrane protein expression of Actinobacillus actinomycetemcomitans and enhance its susceptibility to killing by neutrophilsPenetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil.In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.In vitro activities and targets of three cephem antibiotics against Haemophilus influenzaeDisposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993.Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin.Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs.The in vitro activity of trospectomycin against anaerobic bacteria.Disposition of cefpodoxime proxetil in hemodialysis patients.In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.
P2860
Q33214058-7B924C96-6447-4304-8447-CB370BB14268Q35111643-701B6EF6-6D8F-458D-A1EE-45671D5384B5Q35126031-8253FB32-5D3E-4D88-860B-52C56E5673B7Q35243778-ECC116B1-D67E-43BE-9BCD-8554C4FEA327Q35260298-A24132F1-AADE-4153-B594-FDCA87D226ACQ35358847-88F61F1E-2B8C-4579-AD4C-A2FE05503F4CQ35843322-D85691D1-4AB0-4434-8D18-61D6C6180AFAQ35904342-7B70F486-2FA6-48A6-A609-C0E1346A2629Q37139121-00B999A9-EB98-4250-84F9-0F1379484198Q39871651-B5F93E2E-1085-455B-8CAA-B4A0DD09BA8EQ40596683-B16C5672-3E8C-458D-B1DD-BA905B81B41BQ40803513-0F48A763-F8AF-4E8A-ABB1-613D9FC65333Q43448895-02C15DDA-DF74-4641-A7E8-795591C206A3Q44647933-DF971EAA-FE67-4137-8AD7-110C0222482FQ46369896-15146C2A-2391-4B0D-8C51-F5F6107B3123Q54057919-FF0C7765-6094-46CE-8F0B-E4ECAF6B4CDEQ54293010-C8E80C01-FB63-4E88-814E-C621CACB1516
P2860
Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807)
description
1988 nî lūn-bûn
@nan
1988 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Antimicrobial activity and dis ...... porin ester, U-76,252 (CS-807)
@ast
Antimicrobial activity and dis ...... porin ester, U-76,252 (CS-807)
@en
type
label
Antimicrobial activity and dis ...... porin ester, U-76,252 (CS-807)
@ast
Antimicrobial activity and dis ...... porin ester, U-76,252 (CS-807)
@en
prefLabel
Antimicrobial activity and dis ...... porin ester, U-76,252 (CS-807)
@ast
Antimicrobial activity and dis ...... porin ester, U-76,252 (CS-807)
@en
P2860
P356
P1476
Antimicrobial activity and dis ...... porin ester, U-76,252 (CS-807)
@en
P2093
P2860
P304
P356
10.1128/AAC.32.4.443
P407
P577
1988-04-01T00:00:00Z